These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 19188164)

  • 21. MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines.
    Ohnstad HO; Paulsen EB; Noordhuis P; Berg M; Lothe RA; Vassilev LT; Myklebost O
    BMC Cancer; 2011 May; 11():211:1-11. PubMed ID: 21624110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.
    Cheok CF; Dey A; Lane DP
    Mol Cancer Res; 2007 Nov; 5(11):1133-45. PubMed ID: 18025259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.
    Palani CD; Beck JF; Sonnemann J
    Invest New Drugs; 2012 Feb; 30(1):25-36. PubMed ID: 20680659
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.
    Jones RJ; Bjorklund CC; Baladandayuthapani V; Kuhn DJ; Orlowski RZ
    Mol Cancer Ther; 2012 Oct; 11(10):2243-53. PubMed ID: 22933706
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme.
    Villalonga-Planells R; Coll-Mulet L; Martínez-Soler F; Castaño E; Acebes JJ; Giménez-Bonafé P; Gil J; Tortosa A
    PLoS One; 2011 Apr; 6(4):e18588. PubMed ID: 21483692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
    Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
    Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2.
    Gu L; Zhu N; Findley HW; Zhou M
    Leukemia; 2008 Apr; 22(4):730-9. PubMed ID: 18273046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nutlin-3a is a potential therapeutic for ewing sarcoma.
    Pishas KI; Al-Ejeh F; Zinonos I; Kumar R; Evdokiou A; Brown MP; Callen DF; Neilsen PM
    Clin Cancer Res; 2011 Feb; 17(3):494-504. PubMed ID: 21098696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells.
    Rigatti MJ; Verma R; Belinsky GS; Rosenberg DW; Giardina C
    Mol Carcinog; 2012 May; 51(5):363-78. PubMed ID: 21557332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
    Kojima K; Konopleva M; McQueen T; O'Brien S; Plunkett W; Andreeff M
    Blood; 2006 Aug; 108(3):993-1000. PubMed ID: 16543464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
    Ooi MG; Hayden PJ; Kotoula V; McMillin DW; Charalambous E; Daskalaki E; Raje NS; Munshi NC; Chauhan D; Hideshima T; Buon L; Clynes M; O'Gorman P; Richardson PG; Mitsiades CS; Anderson KC; Mitsiades N
    Clin Cancer Res; 2009 Dec; 15(23):7153-60. PubMed ID: 19934289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53.
    Drakos E; Atsaves V; Schlette E; Li J; Papanastasi I; Rassidakis GZ; Medeiros LJ
    Leukemia; 2009 Dec; 23(12):2290-9. PubMed ID: 19741726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
    Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
    Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.
    Künkele A; De Preter K; Heukamp L; Thor T; Pajtler KW; Hartmann W; Mittelbronn M; Grotzer MA; Deubzer HE; Speleman F; Schramm A; Eggert A; Schulte JH
    Neuro Oncol; 2012 Jul; 14(7):859-69. PubMed ID: 22591662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors.
    Henze J; Mühlenberg T; Simon S; Grabellus F; Rubin B; Taeger G; Schuler M; Treckmann J; Debiec-Rychter M; Taguchi T; Fletcher JA; Bauer S
    PLoS One; 2012; 7(5):e37776. PubMed ID: 22662219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas.
    Crane EK; Kwan SY; Izaguirre DI; Tsang YT; Mullany LK; Zu Z; Richards JS; Gershenson DM; Wong KK
    PLoS One; 2015; 10(8):e0135101. PubMed ID: 26248031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2.
    Cao C; Shinohara ET; Subhawong TK; Geng L; Kim KW; Albert JM; Hallahan DE; Lu B
    Mol Cancer Ther; 2006 Feb; 5(2):411-7. PubMed ID: 16505116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53.
    Cheok CF; Kua N; Kaldis P; Lane DP
    Cell Death Differ; 2010 Sep; 17(9):1486-500. PubMed ID: 20203688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiangiogenic activity of the MDM2 antagonist nutlin-3.
    Secchiero P; Corallini F; Gonelli A; Dell'Eva R; Vitale M; Capitani S; Albini A; Zauli G
    Circ Res; 2007 Jan; 100(1):61-9. PubMed ID: 17138942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma.
    Drakos E; Atsaves V; Li J; Leventaki V; Andreeff M; Medeiros LJ; Rassidakis GZ
    Leukemia; 2009 Apr; 23(4):784-90. PubMed ID: 19225536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.